Participants with moderate or severe CRPS of between @ and @ years duration will be randomly allocated to receive IVIg @ g/kg ( IntratectTM @ g/l solution for infusion ) or matching placebo administered day @ and day @ after randomisation , followed by two optional doses of open-label medication on day @ after randomisation and on day @ after randomisation .